287 related articles for article (PubMed ID: 31375268)
1. When to stop human chorionic gonadotrophin (hCG) surveillance after treatment with chemotherapy for gestational trophoblastic neoplasia (GTN): A national analysis on over 4,000 patients.
Balachandran K; Salawu A; Ghorani E; Kaur B; Sebire NJ; Short D; Harvey R; Hancock B; Tidy J; Singh K; Sarwar N; Winter MC; Seckl MJ
Gynecol Oncol; 2019 Oct; 155(1):8-12. PubMed ID: 31375268
[TBL] [Abstract][Full Text] [Related]
2. Gestational trophoblastic neoplasia after achieving a nondetectable serum human chorionic gonadotrophin level.
Gueye M; Kane-Gueye SM; Ndiaye-Gueye MD; Mbaye M; Diouf AA; Niang MM; Diallo M; Moreau JC
BJOG; 2014 Oct; 121(11):1415-9. PubMed ID: 24674295
[TBL] [Abstract][Full Text] [Related]
3. Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation.
Braga A; Maestá I; Matos M; Elias KM; Rizzo J; Viggiano MG
Gynecol Oncol; 2015 Nov; 139(2):283-7. PubMed ID: 26383828
[TBL] [Abstract][Full Text] [Related]
4. Human Chorionic Gonadotropin (hCG) Regression Curve for Predicting Response to EMA/CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Vincristine) Regimen in Gestational Trophoblastic Neoplasia.
Rattanaburi A; Boonyapipat S; Supasinth Y
Asian Pac J Cancer Prev; 2015; 16(12):5037-41. PubMed ID: 26163637
[TBL] [Abstract][Full Text] [Related]
5. Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia?
Braga A; Biscaro A; do Amaral Giordani JM; Viggiano M; Elias KM; Berkowitz RS; Seckl MJ
Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():50-55. PubMed ID: 29477553
[TBL] [Abstract][Full Text] [Related]
6. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia.
Lybol C; Sweep FC; Harvey R; Mitchell H; Short D; Thomas CM; Ottevanger PB; Savage PM; Massuger LF; Seckl MJ
Gynecol Oncol; 2012 Jun; 125(3):576-9. PubMed ID: 22410329
[TBL] [Abstract][Full Text] [Related]
7. [Clinical analysis of patients with relapsed and chemo-resistant gestational trophoblastic neoplasia].
Zhou Y; Feng FZ; Xiang Y; Wan XR
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):804-7. PubMed ID: 21211275
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors of relapse in low-risk gestational trophoblastic neoplasia patients successfully treated with methotrexate alone.
Couder F; Massardier J; You B; Abbas F; Hajri T; Lotz JP; Schott AM; Golfier F
Am J Obstet Gynecol; 2016 Jul; 215(1):80.e1-7. PubMed ID: 26829503
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study.
Hoeijmakers YM; Sweep F; Lok C; Ottevanger PB
BJOG; 2020 Aug; 127(9):1139-1145. PubMed ID: 32141676
[TBL] [Abstract][Full Text] [Related]
10. Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia.
Winter MC; Tidy JA; Hills A; Ireson J; Gillett S; Singh K; Hancock BW; Coleman RE
Gynecol Oncol; 2016 Dec; 143(3):565-570. PubMed ID: 27756557
[TBL] [Abstract][Full Text] [Related]
11. What is the optimal duration of human chorionic gonadotrophin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients.
Coyle C; Short D; Jackson L; Sebire NJ; Kaur B; Harvey R; Savage PM; Seckl MJ
Gynecol Oncol; 2018 Feb; 148(2):254-257. PubMed ID: 29229282
[TBL] [Abstract][Full Text] [Related]
12. The management and outcome of women with post-hydatidiform mole 'low-risk' gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1).
McGrath S; Short D; Harvey R; Schmid P; Savage PM; Seckl MJ
Br J Cancer; 2010 Mar; 102(5):810-4. PubMed ID: 20160727
[TBL] [Abstract][Full Text] [Related]
13. Management and risk factors of recurrent gestational trophoblastic neoplasia: An update from 2004 to 2017.
Kong Y; Zong L; Cheng H; Jiang F; Wan X; Feng F; Ren T; Zhao J; Yang J; Xiang Y
Cancer Med; 2020 Apr; 9(7):2590-2599. PubMed ID: 32022487
[TBL] [Abstract][Full Text] [Related]
14. Postmolar gestational trophoblastic neoplasia: beyond the traditional risk factors.
Bakhtiyari M; Mirzamoradi M; Kimyaiee P; Aghaie A; Mansournia MA; Ashrafi-Vand S; Sarfjoo FS
Fertil Steril; 2015 Sep; 104(3):649-54. PubMed ID: 26099850
[TBL] [Abstract][Full Text] [Related]
15. Serum hCG level and rising world health organization score at second-line chemotherapy (pulse dactinomycin): poor prognostic factors for methotrexate-failed low-risk gestational trophoblastic neoplasia.
Kang WD; Kim CH; Cho MK; Kim JW; Cho HY; Kim YH; Choi HS; Kim SM
Int J Gynecol Cancer; 2010 Nov; 20(8):1424-8. PubMed ID: 21051988
[TBL] [Abstract][Full Text] [Related]
16. Do we need post-pregnancy screening with human chorionic gonadotrophin after previous hydatidiform mole to identify patients with recurrent gestational trophoblastic disease?
Earp KE; Hancock BW; Short D; Harvey RA; Fisher RA; Drew D; Sarwar N; Tidy JA; Winter MC; Chien P; Seckl MJ
Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():117-119. PubMed ID: 30684876
[TBL] [Abstract][Full Text] [Related]
17. Does hormonal contraception during molar pregnancy follow-up influence the risk and clinical aggressiveness of gestational trophoblastic neoplasia after controlling for risk factors?
Dantas PRS; Maestá I; Filho JR; Junior JA; Elias KM; Howoritz N; Braga A; Berkowitz RS
Gynecol Oncol; 2017 Nov; 147(2):364-370. PubMed ID: 28927899
[TBL] [Abstract][Full Text] [Related]
18. Risk of gestational trophoblastic neoplasia after hCG normalisation according to hydatidiform mole type.
Schmitt C; Doret M; Massardier J; Hajri T; Schott AM; Raudrant D; Golfier F
Gynecol Oncol; 2013 Jul; 130(1):86-9. PubMed ID: 23523617
[TBL] [Abstract][Full Text] [Related]
19. Advances in the clinical laboratory detection of gestational trophoblastic disease.
Seki K; Matsui H; Sekiya S
Clin Chim Acta; 2004 Nov; 349(1-2):1-13. PubMed ID: 15469850
[TBL] [Abstract][Full Text] [Related]
20. Hormonal contraceptive use before hCG remission does not increase the risk of gestational trophoblastic neoplasia following complete hydatidiform mole: a historical database review.
Braga A; Maestá I; Short D; Savage P; Harvey R; Seckl MJ
BJOG; 2016 Jul; 123(8):1330-5. PubMed ID: 26444183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]